-

GE Healthcare’s AIR Recon DL Receives FDA Clearance of 3D & Motion-Insensitive Imaging Applications for Next-Level Image Quality and Patient Experience in MRI

  • Extending deep learning-based AIR Recon DL compatibility to 3D & PROPELLER has the potential to enable more confident patient diagnoses in MRI

CHICAGO--(BUSINESS WIRE)--GE Healthcare announced US FDA 510(k) clearance of its breakthrough AIR Recon DL for 3D and PROPELLER imaging sequences1. The benefits of AIR Recon DL are extended by these new features to nearly all Magnetic Resonance Imaging (MRI) clinical procedures, covering all anatomies and enabling better image quality, shorter scan times, and enhanced patient experience.

Already, GE Healthcare’s AIR Recon DL deep learning-based image reconstruction technology for MRI has fundamentally shifted the balance between image quality and scan time. Now, with the solution’s expanded compatibility from 2D to 3D imaging sequences, physicians can quickly and confidently diagnose patients with improved signal-to-noise ratio (SNR) and sharpness. 3D imaging provides for more clinical efficiency, allowing radiologists to eliminate the need for multiple 2D acquisitions - potentially leading to faster diagnosis.

Additionally, AIR Recon DL is now compatible with PROPELLER, a motion-insensitive imaging sequence particularly important for anatomies susceptible to motion such as respiration during MRI exams, as well as pediatric, neurodegenerative, geriatric, and claustrophobic patients who have difficulty remaining physically still for the duration of an MRI scan. As a result, physicians can get sharper images without the need for repeat scans – translating to faster patient throughput, improved scheduling, shorter exam time, and faster diagnosis, helping to create an all-round better patient experience.

As of September 2022, at least 3.5 million patients globally have been scanned with AIR Recon DL. According to a recent AIR Recon DL 3D and PROPELLER reader study:

  • 100% of the participants said that the deep learning solution provides better signal-to-noise ratio and better or equivalent image sharpness than conventional image reconstruction;
  • 99% also said AIR Recon DL provides better or equivalent lesion conspicuity; and
  • Reports also indicate up to 50% reduction in exam times, creating efficiency in workflow and increased productivity2.

“By expanding AIR Recon DL to 3D and PROPELLER, GE Healthcare has closed the gaps in our ability to provide improved image quality and patient experience to all our patients across exam types, particularly for brain imaging where we rely heavily on 3D sequences and musculoskeletal imaging where PROPELLER is important for reducing image quality variability and eliminating repeat sequences due to motion,” says Dr. Tiron Pechet, Radiologist and Assistant Medical Director at Shields Health Care Group.

AIR Recon DL and the recent extensions are available on new GE Healthcare MRI scanners, and as an upgrade for the vast majority of GE Healthcare’s installed 1.5T and 3.0T MRI systems. Beyond its efficiency and productivity benefits to the industry, this upgrade will enable previously installed scanners to refresh and function like new systems – allowing imaging facilities to enjoy the most advanced imaging capabilities on their existing systems, while saving on capital expenditure amid today’s cost constrained environment.

About GE Healthcare:

GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

1 510(k) cleared in the USA. Not CE marked, not available for sale in all regions.

2 GE Healthcare data on file.

Contacts

Maureen Oladipo
Maureen.Oladipo@ge.com
+1 229 418 4479

GE Healthcare

NYSE:GE

Release Versions

Contacts

Maureen Oladipo
Maureen.Oladipo@ge.com
+1 229 418 4479

More News From GE Healthcare

GE HealthCare launches ReadyFix fleet management solution to help enhance operational efficiency and reliable patient care

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the United States launch of ReadyFix™, a remote fleet management solution designed to help healthcare systems support device uptime. ReadyFix will seamlessly integrate with GE HealthCare’s MAC VU360™ resting ECG workstations, which are designed to deliver high-quality ECG readings that help clinicians make faster, more confident cardiac care decisions. When paired with ReadyFix, healthcare systems can leverage real-time** da...

GE HealthCare reports fourth quarter and full year 2025 financial results

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. GE HealthCare President and CEO Peter Arduini said, “In our third year as a public company, we’ve made great strides executing our strategy focused on precision care, growth acceleration, and business optimization. We delivered a strong quarter and year with growth in Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions. This...

GE HealthCare announces U.S. FDA 510(k) clearance and CE Mark for Allia Moveo and marks first global installation, advancing precision care in the interventional suite

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite. The latest Allia platform, one of the company’s bold innovations first unveiled at the Radiological Society of North America’s (RSNA) 2025 Annual Meeting, assists clinicians in a wide range of cardiovascular, vascular, non-vascular, interventional and...
Back to Newsroom